| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 426.56 | 422.71 | 331.02 | 520.5 | 456.54 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 426.56 | 422.71 | 331.02 | 520.5 | 456.54 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 20.35 | 48.28 | 119.88 | 6.92 | 5.16 |
Total Income | 446.91 | 470.99 | 450.9 | 527.42 | 461.7 |
Total Expenditure | 425.59 | 436.73 | 423.31 | 504.17 | 382.29 |
PBIDT | 21.32 | 34.26 | 27.59 | 23.25 | 79.41 |
Interest | 2.84 | 2.76 | 3.39 | 150.18 | 138.43 |
PBDT | 18.48 | 31.5 | 24.2 | -126.93 | -59.02 |
Depreciation | 26.39 | 27.9 | 29.61 | 32.51 | 34.02 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0 | 0.62 | 0 | 0 | 0.03 |
Deferred Tax | -1.18 | 2.49 | 15.66 | 0.12 | 0.44 |
Reported Profit After Tax | -6.73 | 0.49 | -21.07 | -159.56 | -93.51 |
Minority Interest After NP | -0.25 | 0.23 | 0 | -0.03 | 0.08 |
Net Profit after Minority Interest | -6.48 | 0.26 | -21.07 | -159.53 | -93.59 |
Extra-ordinary Items | 8.28 | 30.18 | 67.62 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | -14.76 | -29.92 | -88.69 | -159.53 | -93.59 |
EPS (Unit Curr.) | -1.06 | 0.04 | -3.44 | -26.05 | -15.27 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 4.99 | 8.1 | 8.33 | 4.46 | 17.39 |
PBDTM(%) | 4.33 | 7.45 | 7.31 | -24.38 | -12.92 |
PATM(%) | -1.57 | 0.11 | -6.36 | -30.65 | -20.48 |
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
